Johnson & Johnson Beats on Earnings, Hikes Forecast
JNJ Stock Raises Forecast for Full Year
New York, NY — Healthcare giant Johnson & Johnson (NYSE:JNJ) reported a better-than-expected rise in quarterly sales, helped by strength in its pharmaceuticals business.
Johnson & Johnson raised its 2016 sales and earnings forecast and reported quarterly results that beat Wall Street estimates. Net earnings and diluted earnings-per-share for the second quarter of 2016 were $4.0 billion and $1.43 billion, respectively. (Source: “Johnson & Johnson Announces Quarterly Dividend,” PR Newswire, July 18, 2016)
“We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by strong underlying growth across our enterprise,” said Alex Gorsky, chairman and chief executive officer. “We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline.” (Source: Ibid.)
The company increased its sales guidance for the full-year 2016 to $71.5 billion–$72.2 billion, up from the from $71.2 billion–$71.9 billion previously estimated. Additionally, the company increased its adjusted earnings guidance for full-year 2016 to $6.63–$6.73 per share, the company said on its web site. (Source: “Johnson & Johnson Reports 2016 Second-Quarter Results,” July 19, 2016)
Dear Reader: There is no magic formula to getting rich. Success in investment vehicles with the best prospects for price appreciation can only be achieved through proper and rigorous research and analysis. We are 100% independent in that we are not affiliated with any bank or brokerage house. Information contained herein, while believed to be correct, is not guaranteed as accurate. Warning: Investing often involves high risks and you can lose a lot of money. Please do not invest with money you cannot afford to lose. The opinions in this content are just that, opinions of the authors. We are a publishing company and the opinions, comments, stories, reports, advertisements and articles we publish are for informational and educational purposes only; nothing herein should be considered personalized investment advice. Before you make any investment, check with your investment professional (advisor). We urge our readers to review the financial statements and prospectus of any company they are interested in. We are not responsible for any damages or losses arising from the use of any information herein. Past performance is not a guarantee of future results. All registered trademarks are the property of their respective owners
Sign up to receive our FREE Income Investors newsletter along with our special offers and get our FREE report:
5 Dividend Stocks to Own Forever
This is an entirely free service. No credit card required. You can opt-out at anytime.
We hate spam as much as you do.